Smartleaf Asset Management LLC Raises Holdings in argenx SE (NASDAQ:ARGX)

Smartleaf Asset Management LLC increased its position in argenx SE (NASDAQ:ARGX) by 205.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 272 shares of the company’s stock after buying an additional 183 shares during the quarter. Smartleaf Asset Management LLC’s holdings in argenx were worth $169,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ARGX. FMR LLC raised its position in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the period. Lord Abbett & CO. LLC acquired a new stake in argenx in the 3rd quarter valued at $88,339,000. Allspring Global Investments Holdings LLC increased its holdings in argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after purchasing an additional 143,834 shares in the last quarter. Jennison Associates LLC increased its holdings in argenx by 27.0% in the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in argenx by 13.0% in the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock valued at $261,470,000 after purchasing an additional 55,617 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Performance

NASDAQ:ARGX opened at $613.18 on Friday. The company has a market capitalization of $37.26 billion, a price-to-earnings ratio of -696.80 and a beta of 0.58. argenx SE has a one year low of $349.86 and a one year high of $678.21. The stock has a 50-day simple moving average of $642.47 and a 200 day simple moving average of $592.89.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. On average, equities research analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ARGX shares. Wedbush reiterated an “outperform” rating and issued a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. JMP Securities increased their price target on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Evercore ISI increased their price target on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Wells Fargo & Company increased their price target on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Finally, Piper Sandler raised their target price on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and a consensus price target of $662.83.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.